Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Grand Pharmaceutical Group Limited ( (HK:0512) ).
Grand Pharmaceutical Group Limited announced that its associate company, Sirtex Medical Pty Ltd, received early FDA approval for a new indication of its SIR-Spheres® Y-90 resin microsphere injection, now approved for treating unresectable hepatocellular carcinoma (HCC). This approval highlights the company’s strong clinical registration capabilities and supports its strategy to expand its nuclear medicine offerings globally, reinforcing its leadership in the industry. The product, which has been widely adopted and recognized for its effectiveness, is expected to enhance the company’s market position and provide significant growth opportunities.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on innovative nuclear medicine products. The company emphasizes research and development, leveraging a global strategic plan for nuclear medicine to create a comprehensive ecosystem that integrates diagnosis and treatment across domestic and international markets.
Average Trading Volume: 31,403,985
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.72B
For a thorough assessment of 0512 stock, go to TipRanks’ Stock Analysis page.